BioSpace News Archive

The American Association of Oral and Maxillofacial Surgeons honored more than 20 award recipients for their accomplishments in education, research, advocacy and humanitarianism at the association’s 2020 Virtual Annual Meeting, Scientific Sessions and Exhibition.

bEquinox Ophthalmic, Inc, an early-stage medical device company that is developing a new paradigm to revolutionize the treatment of glaucoma and other progressive eye diseases, announced the appointment of Stuart Raetzman as Executive Chairman.

Exact Sciences Corp. and Pfizer Inc. announced an extension and amendment of their agreement to promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer.

Global Mercy will deliver free, world-class surgical care to patients in African nations who lack healthcare access

Heat Biologics, Inc. announced it has been issued a new US patent covering compositions of matter that are part of Heat’s gp96 platform in combination with Inducible T cell Co-stimulator ligand or ICOSL, a T cell immune booster, in a single therapy.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will participate in two upcoming virtual investor events in October.

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its financial results for the third quarter of 2020 after the close of market on Monday, November 2, 2020.

Companies to broaden their existing partnership on Age-related Macular Degeneration (AMD) treatments OliX grants Théa worldwide rights excluding Asia-Pacific on OLX301A and OLX301D, targeting dry/wet AMD and wet AMD/subretinal fibrosis, respectively OliX further grants Théa option to nominate two additional ophthalmic programs Théa to invest €8.8 million through upfront payment for two AMD programs and an option fee for two additional ophthalmic programs SUWON, Republic of Korea and CLERMON

Synthego, the genome engineering company, today announced the design of new foundational technology for standardized precision and control of CRISPR-based gene editing inside cells using light.

Phenomic AI, a biotech using AI/ML to reveal drug targets that emerge from cell-cell interactions and drive novel antibody drug discovery for challenging diseases, today announced the official launch of the company with US$6 million seed financing.